Sun Pharmaceutical Industries Ltd Share Price
(SUNPHARMA)
₹1775.2▲1.59%
as on 12:54PM, 23 Apr 2025
🔔 Growth Alert
Sun Pharma expected to deliver 12% YoY growth in the US market, driven by its specialty portfolio, according to Centrum.
Day's Low
Day's High
52 Week's Low
52 Week's High
Returns % | |
1 Month Return | -2.1 % |
3 Month Return | -4.7 % |
1 Year Return | + 17.7 % |
Market Stats | |
Previous Close | ₹1,747.40 |
Open | ₹1,775.30 |
Volume | 6.72L |
Upper Circuit | ₹1,922.10 |
Lower Circuit | ₹1,572.70 |
Market Cap | ₹4,19,259.79Cr |
P/E Ratio
36.63
PEG Ratio
3.46
Market Cap
₹4,19,259.79 Cr
P/B Ratio
16.41
EPS
40.21
Dividend Yield
0.83
Sector
Pharmaceuticals
ROE
12.05
based on 37 analysts
81.08%
Buy
10.81%
Hold
8.11%
Sell
Based on 37 analysts offering long term price targets for Sun Pharma. An average target of ₹2047.89
Source: S&P Global Market Intelligence
Sun Pharma price forecast by 37 analysts
Upside of17.20%
High
₹2450
Target
₹2047.89
Low
₹1500
Sun Pharma target price ₹2047.89, a slight upside of 17.2% compared to current price of ₹1775.2. According to 37 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Sun Pharma revenue growth forecast
Expected growth rate Q1, FY2027:32.23%
Forecast
Actual
Including amortisation and stock based compensations
Sun Pharma EPS growth forecast
EPS estimate Q1, FY2027:56.55%
Forecast
Actual
Source: S&P Global Market Intelligence
Today's Timeline - Invalid Date
10:09 AM
-Sun Pharma expected to achieve 12% YoY growth in the US market, driven by its specialty portfolio.
Sun Pharma Shares Rise with Buy Recommendation - 20 Apr, 2025
Sun Pharma Faces Recall Amid Regulatory Challenges - 14 Apr, 2025
Sun Pharma Faces Recall Amid Stock Recovery - 13 Apr, 2025
Sun Pharma Gains Court Approval for Leqselvi Launch - 10 Apr, 2025
Sun Pharma Faces Challenges from US Tariff Announcement - 09 Apr, 2025
Sun Pharma Launches New Drug Amid Market Challenges - 07 Apr, 2025
Sun Pharma Faces Tariff Concerns Amid Growth Prospects - 04 Apr, 2025
Sun Pharma Shares Surge on Tariff Exemption News - 03 Apr, 2025
Sun Pharma Reports Strong Growth Amid Challenges - 02 Apr, 2025
Concerns Over Tariffs Impacting Pharma Sector - 30 Mar, 2025
Sun Pharma Enters Merger Agreement with Checkpoint Therapeutics - 29 Mar, 2025
Sun Pharma Faces Challenges Amid Market Decline - 27 Mar, 2025
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Retail Holding Up
Retail Investor have increased holdings from 8.89% to 8.92% in Dec 2024 quarter
FII Holding Up
Foreign Institutions have increased holdings from 18.02% to 18.05% in Dec 2024 quarter
MF Holding Up
Mutual Funds have increased holdings from 12.11% to 12.24% in Dec 2024 quarter
Revenue Rich
Revenue is up for the last 4 quarters, 12.58K Cr → 14.14K Cr (in ₹), with an average increase of 3.8% per quarter
Promoter Holding Unchanged
Promoters holdings remained unchanged at 54.48% of holdings in Dec 2024 quarter
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 137.6% return, outperforming this stock by 43.5%
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 56.9% return, outperforming this stock by 39.2%
Profit Down
Netprofit is down for the last 2 quarters, 3.04K Cr → 2.90K Cr (in ₹), with an average decrease of 4.5% per quarter
Price Dip
In the last 1 month, SUNPHARMA stock has moved down by -2.1%
Investors | Holdings % | FY Quarter | 3M change |
---|---|---|---|
Promoter Holdings | 54.48% | 0.00 | |
Foreign Institutions | 18.05% | 0.17 | |
Mutual Funds | 12.24% | 1.02 | |
Retail Investors | 8.92% | 0.33 | |
Others | 6.31% |
Sun Pharma in the last 5 years
Lowest (19.47x)
March 23, 2020
Today (36.63x)
April 22, 2025
Industry (53.69x)
April 22, 2025
Highest (184.63x)
August 28, 2020
Sun Pharmaceutical Industries Ltd’s net profit jumped 15.04% since last year same period to ₹2,903.38Cr in the Q3 2024-2025. On a quarterly growth basis, Sun Pharmaceutical Industries Ltd has generated -4.5% fall in its net profits since last 3-months.
Read More about Earnings ResultsIn the quarter ending December 2024, Sun Pharmaceutical Industries Ltd has declared dividend of ₹10.50 - translating a dividend yield of 1.37%.
Read More about DividendsBearish
Neutral
Bullish
Sun Pharmaceutical Industries Ltd is currently in a Bullish trading position according to technical analysis indicators.
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
---|---|---|---|---|---|---|
BUY | ₹4,19,259.79 Cr | 53.2% | 0.68 | ₹9,648 Cr | ₹48,496 Cr | |
HOLD | ₹1,56,931.75 Cr | 28.91% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
BUY | ₹1,09,867.99 Cr | 33.6% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
BUY | ₹40,076.03 Cr | -0.8% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
HOLD | ₹23,904.51 Cr | -4.05% | 0.50 | ₹772 Cr | ₹5,664 Cr |
Organisation | Sun Pharma |
Headquarters | Mumbai |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Sun Pharmaceutical Industries Ltd share price today stands at ₹1775.2, Open: ₹1775.3, Previous Close: ₹1747.4, High: ₹1777.5, Low: ₹1742.1, 52 Week High: ₹1960.35, 52 Week Low: ₹1377.2.
Today's traded volume of Sun Pharmaceutical Industries Ltd(SUNPHARMA) is 6.72L.
Today's market capitalisation of Sun Pharmaceutical Industries Ltd(SUNPHARMA) is ₹419259.79Cr.
Sun Pharmaceutical Industries Ltd (SUNPHARMA) share price is ₹1775.2. It is down -9.44% from its 52 Week High price of ₹1960.35
Sun Pharmaceutical Industries Ltd (SUNPHARMA) share price is ₹1775.2. It is up 28.90% from its 52 Week Low price of ₹1377.2